Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce results showing a significant reduction in the PromarkerD risk scores of patients with type 2 diabetes after taking the diabetes medicine canagliflozin.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide the following update on its business activities for the three months to 31 March 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has appointed additional members to its Clinical Advisory Board adding world leading healthcare professionals from the United States.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the National Association of Testing Authorities (NATA) of Australia has approved the continuation of the Company's ISO 17025 accreditation.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its potential new world-first blood test for diagnosing endometriosis.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the application for PromarkerD's listing on the Australian Medicare Benefits Schedule hosted by MD, Dr Richard Lipscombe.
Proteomics International Laboratories Ltd (ASX:PIQ) advises that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company's PromarkerD predictive test for diabetic kidney disease in the United States.
